A bench headed by Justice G S Singhvi granted two weeks time to the Centre to issue notification and posted the matter for hearing on December 12.
Additional Solicitor General Siddharth Luthra informed the court that the Cabinet had approved the policy that will bring 348 essential drugs under price control on November 22 and it will soon be notified.
The court was hearing a public interest litigation plea filed in 2003 by All India Drugs Action Network and others which had complained that currently only around 78 drugs are placed under the Drugs (Prices Control) Order, 1995 (DPCO) making rest of the medicines beyond the reach of the common man.
Referring to media reports about the new policy, the petitioner submitted that price of essential medicines will go up after its notification.
But the bench said it would not go by the media reports and said it would examine the policy itself after the same is notified.
The apex court had set November 27 as deadline for the government to finalise the policy while asking it not to alter the existing mechanism of cost-based drug pricing.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
